Jan 26- The U.S. Food and Drug Administration said it approved Teva Pharmaceutical Industries Ltd's generic version of AstraZeneca Plc's blockbuster heartburn drug Nexium, the agency's first such approval for the drug. Nexium raked in about $1.9 billion in global sales in the first half of 2014, according to AstraZeneca's latest earnings statement.
Dec 5- A Massachusetts jury has found that an agreement between AstraZeneca Plc and Ranbaxy Laboratories Ltd to delay the launch of a generic version of AstraZeneca's heartburn drug Nexium was not anticompetitive. AstraZeneca and an attorney for Ranbaxy released statements saying they were pleased with the verdict. The lawsuit, which began in 2012,...
WASHINGTON, Nov 26- Switzerland's Novartis AG has agreed to sell its nicotine patch, Habitrol, in order to win U.S. antitrust approval for a consumer healthcare joint venture with Britain's GlaxoSmithKline, the U.S. Federal Trade Commission said on Wednesday. The deal is part of a three-way transaction unveiled in April, which includes GSK buying Novartis'...
Nov 20- A U.S. court has denied a request by Indian drugmaker Ranbaxy Laboratories Ltd to stop competitors from launching copies of AstraZeneca Plc's heartburn pill Nexium and Roche's antiviral, a court filing showed. Ranbaxy had filed a lawsuit against the U.S. Food and Drug Administration last week for revoking tentative approvals it gave the company to make...
Nov 20- A U.S. court has denied a request by Indian drugmaker Ranbaxy Laboratories Ltd to stop competitors from launching copies of AstraZeneca Plc's heartburn pill Nexium and Roche's antiviral Valcyte, a court filing showed. Ranbaxy had sought the restraining order against Dr Reddy's Laboratories and U.S. firm Endo International Plc in a lawsuit it filed...
*Ranbaxy says FDA revoked approval for copies of Nexium, Valcyte. *FDA said approvals were given "in error"- Ranbaxy. The FDA has also stripped Ranbaxy of tentative approval and six-month exclusivity for a copy of Roche Holding AG's antiviral Valcyte, a fresh blow to the Indian company that has been hit by a raft of regulatory bans over poor production quality.
Sept 15- Epirus Biopharmaceuticals Inc said India's drug regulator has approved its copy of a top-selling arthritis treatment, paving the way for its launch in the country early next year.
January is a little more than half over and already these shares have gained almost 50% ytd. What's the story?
U.S. stock index futures signaled a lower open on Tuesday, as fears that China's central bank will not provide stimulus to boost its economy saw the Shanghai Composite fall to a one-week low.
The Food and Drug Administration on Wednesday asked Teva Pharmaceuticals to withdraw its drug Budeprion XL 300 after testing showed the drug did not properly release its key ingredient.
With violence in the Middle East triggering a rotation out of emerging markets, how should you trade, especially if you still believe in the EM story?
Ron Shah Of Jina Ventures suggests putting money to work overseas in these 10 stocks.
Indian stocks have been sliding since the New Year amid inflation fears but there are still places where investors can get in, said Ron Shah, managing partner at Jina Ventures.
With President Obama visiting the Subcontinent, Ron Shah of Jina Ventures recommends playing these Indian companies in the long-term.
India's stock market has jumped almost 19% over the past year, far outpacing the Dow Jones Industrial Average, and it may not be done yet....A report from TheStreet.
With Barron’s turning very bullish on generic drugmaker Mylan Labs, should you put money to work in the generic space?
It seems new taxes on outside investors looking to play Brazil can’t dampen enthusiasm about emerging markets!
A decisive win by India's capitalism party over rival communists triggered the largest gains in stocks in about two decades. How should you be trading?
Indian stocks that trade in the U.S. are up double digits as stock trading in India was halted for the first time because of a surge in stock prices on the big election victory for Prime Minister Singh's Congress Party.
Today was really ugly for biotech. The only large-cap sector stock to trade higher--and significantly--was Genentech because it's being bolstered by Roche's bond sale and increasing speculation the Swiss drugmaker is gonna have to raise its bid for DNA.